(Q37564485)

21 August 2017

1 reference

title

Overcoming drug resistance in patients with metastatic breast cancer (English)

1 reference

21 August 2017

0 references

1 reference

Serena T Wong

1

1 reference

PubMed ID

19637949

21 August 2017

Susan Goodin

series ordinal

2

1 reference

PubMed ID

19637949

21 August 2017

language of work or name

English

0 references

publication date

1 August 2009

1 reference

21 August 2017

1 reference

21 August 2017

29

1 reference

21 August 2017

954-965

1 reference

21 August 2017

8

1 reference

Molecular mechanisms of drug resistance

21 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Taxanes in breast cancer: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Metastatic breast cancer: the treatment challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

The translocation mechanism of P-glycoprotein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Bcl-2 and the regulation of programmed cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Thymidine phosphorylase and dihydropyrimidine dehydrogenase are predictive factors of therapeutic efficacy of capecitabine monotherapy for breast cancer-preliminary results

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Clinical pharmacology of 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Microtubules as a target for anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Microtubule polymerization dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

p53, the cellular gatekeeper for growth and division

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Estrogen receptors outside the nucleus in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

The ErbB signaling network: receptor heterodimerization in development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Oncogenic kinase signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

TGFalpha expression impairs Trastuzumab-induced HER2 downregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Salvage treatment of metastatic breast cancer with docetaxel and carboplatin. A multicenter phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Monthly docetaxel and weekly gemcitabine in metastatic breast cancer: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Herceptin alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Epothilones: mechanism of action and biologic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

The epothilones: translating from the laboratory to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.8.954

21 January 2018

Identifiers

DOI

10.1592/PHCO.29.8.954

1 reference

21 August 2017

1 reference

PubMed ID

19637949